You are here: Home » News-ANI » National
Business Standard

HC to pronounce verdict on Centre's ban on 344 FDC medicines today

ANI  |  New Delhi [India] 

The High is likely to pronounce its verdict on 454 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines today.

The drugs include brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies and some NGOs.

The had on March 14 stayed the Centre's March 10 ban on 344 drugs and this interim order was passed in each and every case filed before it thereafter.

During arguments, the drug companies had argued that the ban order was passed without considering clinical data and had termed as "absurd" the government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.

The had banned over 300 drugs on the ground that they involve "risk" to humans and safer alternatives were available.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

HC to pronounce verdict on Centre's ban on 344 FDC medicines today

The Delhi High Court is likely to pronounce its verdict on 454 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines today.The drugs include brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies and some NGOs.The court had on March 14 stayed the Centre's March 10 ban on 344 FDC drugs and this interim order was passed in each and every case filed before it thereafter.During arguments, the drug companies had argued that the ban order was passed without considering clinical data and had termed as "absurd" the government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.The government had banned over 300 FDC drugs on the ground that they involve "risk" to humans and safer alternatives were available.

The High is likely to pronounce its verdict on 454 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines today.

The drugs include brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies and some NGOs.

The had on March 14 stayed the Centre's March 10 ban on 344 drugs and this interim order was passed in each and every case filed before it thereafter.

During arguments, the drug companies had argued that the ban order was passed without considering clinical data and had termed as "absurd" the government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.

The had banned over 300 drugs on the ground that they involve "risk" to humans and safer alternatives were available.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

HC to pronounce verdict on Centre's ban on 344 FDC medicines today

The High is likely to pronounce its verdict on 454 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines today.

The drugs include brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies and some NGOs.

The had on March 14 stayed the Centre's March 10 ban on 344 drugs and this interim order was passed in each and every case filed before it thereafter.

During arguments, the drug companies had argued that the ban order was passed without considering clinical data and had termed as "absurd" the government's claim that it took the decision to ban FDCs on the ground that safer alternatives were available.

The had banned over 300 drugs on the ground that they involve "risk" to humans and safer alternatives were available.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard